Loading…
Loading…
would you talk a little bit about how your expansion strategy into primary care is going
Can you talk a little bit about how you think about this competition over time versus Skyrizi or Rinvoq
as you saw with HUMIRA biosimilar, people decided to not move change to biosimilar, but to a more efficacious drug like Skyrizi and Rinvoq
Do you think there's a strategy to just use this as a single agent, especially among patients who cannot tolerate GLP-1
it still seems like the volume or IRA space is growing rapidly. Can you talk a little bit about the underlying dynamics
can you please remind us what percentage of your prescriptions are coming from primary care at this point? And with the Vesilius data, like how do you see the primary case segment of the market evo...
how should we think about the cadence of a biosimilar erosion with the biosimilars coming? I'm assuming it is more back-half loaded
Now that you are guiding for 5% year-over-year growth, combine that with the $900 million of Part D redesign impact you're taking, does seem like HIV is growing at, what, 9% to 10%
the logistics dynamic because this is a prescriber base that is used to orals and now they're going to use an injection
about the NIH funding cuts and potential for funding cuts regarding something which could help with the HIV awareness
did you see a more than normal inventory buildup in fourth quarter because you're calling out year-over-year as well
what is your latest thinking on the importance of getting obesity-related indications on the label
How do you think about this space evolving? And could brenipatide the new GLP/GIP be a drug for Alzheimer's given that this has neuro properties
if you could comment on the gender split in the orforglipron study, if there was any difference versus any other trials for GLP-1
the other way could be, I mean, looking at CVS comments, it seems like a lot of our employers did not opt in and CVS is finding a way to actually provide affordable access
how have the discussions with the prescribers as well as payers have gone so far? The one pushback we hear is that these patients are often treated by sleep specialists
should we expect an interim disclosure in March or after March or not
if I compare the guidance on an FX basis versus the prior quarter, it does seem like you lowered
it doesn't seem like they are innovative area. Right? And all I did I think you are the first mover here
have you commented on how much inventory Zhifei had at this point with GARDASIL